top of page
Latest News

News: Latest News

Code Biotherapeutics Appoints Lauren M. Kaskiel, MBA as Chief Business Officer

- Industry veteran will draw on 20-year background in pharma and biotech to enhance partnerships and help advance use of company’s novel targeted non-viral gene delivery (3DNA) platform

Hatfield, PA — April 16, 2021 — Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and genetic diseases,  announces today that Lauren M. Kaskiel, MBA will join the company as its Chief Business Officer.

“I’m thrilled to welcome Lauren to the team,” said Chief Executive Officer, Chairman and Co-Founder Brian P. McVeigh. “Her breadth of experience delivering value from mutually beneficial collaborations in both biotech and pharma companies significantly strengthens our business development capabilities, and her depth of  scientific knowledge and program management experience will enable the efficient advancement of our internal pipeline.”

Ms. Kaskiel has 20 years of experience in the biotech and pharmaceutical industry. She most recently held roles at Spark Therapeutics, as Head of Program and Alliance Management and previously in New Product Planning and Alliance Management. During her tenure at Spark, she established and managed key strategic relationships for gene therapy programs with Pfizer and Novartis. She also served as a liaison with the Roche Group to support engagement and interactions following its acquisition of Spark, where she contributed to defining the operating model and governance for Spark and served as Chief of Staff to the Executive Team.

Previously, Ms. Kaskiel worked at GlaxoSmithKline (GSK) as part of GSK’s Worldwide Business Development team, where she managed over 20 alliances with biotech, diagnostic and venture partners. She holds a Bachelor of Science degree in Biotechnology with a Minor in Microbiology from Pennsylvania State University and an MBA with a Concentration in Marketing from Drexel University.

“It’s an honor to join this team of innovators whose mission is to make a lasting difference in the lives of patients with rare and prevalent genetic disorders,” said Ms. Kaskiel. “Code Bio’s 3DNA platform is truly exciting because of its potential to provide meaningful gene therapy solutions across numerous indications. I look forward to facilitating relationships with partners who can contribute to the advancement of this invaluable technology.”

About Code Bio therapeutics, Inc.

Headquartered in Greater Philadelphia, Code Bio is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases.  Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases. For more information, visit


Media Contact:

Mike Beyer
Sam Brown Inc. Healthcare Communications


bottom of page